CD7CAR
Showing 1 - 25 of >10,000
Hematologic Diseases, Tumors Trial in Hangzhou (CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation)
Recruiting
- Hematologic Diseases
- Neoplasms
- CD7 CAR-T cells injection
- Allogeneic hematopoietic stem cell transplantation
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Apr 11, 2023
T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- CD7 CAR-T cells
-
Shenzhen, Guangdong, ChinaLi Yu
Nov 11, 2022
Hematological Malignancies Trial (Anti-CD7 CAR-T)
Not yet recruiting
- Hematological Malignancies
- Anti-CD7 CAR-T
- (no location specified)
Jul 8, 2022
T-Cell Acute Lymphocytic Leukemia Trial in Langfang (CD7 CAR-T)
Recruiting
- T-Cell Acute Lymphocytic Leukemia
- CD7 CAR-T
-
Langfang, Hebei, ChinaHebei Yanda Hospital
Jun 26, 2023
Tumors, Hematologic Tumors, Tumors by Site Trial in Hangzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +3 more
- RD13-02 cell infusion
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Feb 6, 2023
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Kunming (Target CD7 CAR-T cells)
Withdrawn
- T-cell Acute Lymphoblastic Leukemia
- T-lymphoblastic Lymphoma
- Target CD7 CAR-T cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Nov 23, 2022
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
-
Shanghai, ChinaXianmin General Song
Aug 29, 2022
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma Trial in Langfang (CD7CAR T cells)
Recruiting
- Relapsed/Refractory, High Risk Hematologic Malignancies
- T-ALL/Lymphoma
- CD7CAR T cells
-
Langfang, Hebei, ChinaHebei Yanda Lu Daopei Hospital
Jun 30, 2022
Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CAR-T Therapy
-
Hefei, Anhui, China
- +7 more
Jul 31, 2023
CD7+ Acute Leukemia, CD7+ Lymphoma Trial in Hangzhou (anti-CD7 CAR-T)
Recruiting
- CD7+ Acute Leukemia
- CD7+ Lymphoma
- anti-CD7 CAR-T
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
Sep 18, 2022
T-lymphoblastic Lymphoma, T-ALL Trial in Shanghai (CAR-T)
Recruiting
- T-lymphoblastic Lymphoma
- T-ALL
- CAR-T
-
Shanghai, ChinaShanghai Ruijin Hospital
Nov 14, 2023
T Cell Lymphoma, T-cell Leukemia Trial in Beijing (chimeric antigen receptor T cell treatment)
Recruiting
- T Cell Lymphoma
- T-cell Leukemia
- chimeric antigen receptor T cell treatment
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Aug 12, 2022
Crohn Disease, Ulcerative Colitis, Dermatomyositis Trial in Hangzhou (CD7 CAR T-cells)
Recruiting
- Crohn Disease
- +4 more
- CD7 CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Feb 13, 2022
T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Relapse/Recurrence Trial in Beijing (chimeric antigen
Recruiting
- T-cell Leukemia/Lymphoma
- +2 more
- chimeric antigen receptor T cell treatment
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Jul 31, 2022
T Cell Lymphoblastic Lymphoma Trial in Beijing (BT-007 CD7 CAR-T cells)
Recruiting
- T Cell Lymphoblastic Lymphoma
- BT-007 CD7 CAR-T cells
-
Beijing, ChinaBeijing Cancer Hospital
Sep 22, 2022
T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma Trial in Wuhan (Fludarabine +
Recruiting
- T-Cell Lymphocytic Leukemia
- +2 more
- Fludarabine + Cyclophosphamide + CAR7-T Cells
-
Wuhan, Hubei, ChinaUnion Hospital, Huazhong University of Science and Technology
Mar 1, 2022
Refractory and Relapsed T Cell Lymphoma Trial in Suzhou (Humanized CD7 CAR-T cells)
Recruiting
- Refractory and Relapsed T Cell Lymphoma
- Humanized CD7 CAR-T cells
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 17, 2021
T-cell Acute Lymphoblastic Leukemia/Lymphoma Trial in Beijing (Senl-T7)
Recruiting
- T-cell Acute Lymphoblastic Leukemia/Lymphoma
- Senl-T7
-
Beijing, Hebei, ChinaHebei yanda Hospital
Nov 22, 2022
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Xuzhou, Jiangsu, ChinaAffiliated hospital of Xuzhou medical college
Jun 7, 2023
Diffuse Large B-cell Lymphoma Trial in Hangzhou, Ningbo (CD19-7×19 CAR-T combined with Tislelizumab)
Recruiting
- Diffuse Large B-cell Lymphoma
- CD19-7×19 CAR-T combined with Tislelizumab
-
Hangzhou, Zhejiang, China
- +1 more
Dec 12, 2022
Leukemia, T Cell Trial in Beijing (CD7 CART)
Recruiting
- Leukemia, T Cell
- CD7 CART
-
Beijing, Hebei, ChinaHe bei Yan da Lu dao pei Hospital
May 24, 2022
Lymphoma, T-Cell Trial in Yanda (Senl-T7)
Recruiting
- Lymphoma, T-Cell
- Senl-T7
-
Yanda, Hebei, ChinaHebei yanda Ludaopei Hospital
May 24, 2022
Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (BEAM-201)
Recruiting
- Lymphoblastic Lymphoma
- +2 more
- BEAM-201
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jun 2, 2023
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- +3 more
- Universal CD7-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 17, 2023